IDEV - ETF AI Analysis
Top Page
iShares Core MSCI International Developed Markets ETF (IDEV)
Rating:66Neutral
Price Target:―
Positive Factors
Low Expense Ratio
The fund charges a very low fee, which helps investors keep more of their returns over time.
Broad International Diversification
Holdings spread across many developed countries like Japan, the UK, Europe, Canada, and others help reduce the impact of problems in any single market.
Healthy Size and Recent Performance
The ETF has a large asset base and has shown steady gains over the past month, three months, and year-to-date, suggesting it is widely used and has been performing reasonably well.
Negative Factors
Heavy Tilt to Financials and Industrials
A large share of the portfolio is in financial and industrial companies, which can hurt returns if these sectors struggle.
Mixed Results Among Top Holdings
While some leading positions like ASML, Roche, Siemens, Toyota, and others have been strong, several other major holdings have been weak, which can drag on overall performance.
Limited Exposure to High-Growth Tech
Technology makes up a relatively small part of the portfolio, so the fund may benefit less if global tech stocks outperform.
IDEV vs. SPDR S&P 500 ETF (SPY)
AUM26.69B
RegionDeveloped Markets
Expense Ratio0.04%
Beta0.74
IssueriShares
Inception DateMar 21, 2017
Dividend Yield3.36%
Asset ClassEquity
Index TrackedMSCI World ex USA IMI
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,226,117
30 Day Avg. Volume2,807,002
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
111.83Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2233
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDEV Summary
IDEV is an ETF that tracks the MSCI World ex USA IMI index, giving you broad exposure to stocks in developed countries outside the U.S. and Canada. It owns thousands of companies across many sectors and regions, including well-known names like Nestlé, Toyota, and ASML. Someone might invest in IDEV to diversify beyond the U.S. market and tap into long-term growth in Europe, Japan, and other developed economies, all in a single fund. A key risk is that international stock prices can go up and down with global markets and currency swings.
How much will it cost me?The iShares Core MSCI International Developed Markets ETF (IDEV) has an expense ratio of 0.04%, meaning you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically costs less to operate compared to actively managed funds.
What would affect this ETF?Positive drivers for IDEV could include economic growth in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare, which are heavily represented in the ETF. However, negative factors such as rising interest rates or geopolitical tensions in Europe and Asia could impact the performance of key holdings like ASML, Nestlé, and HSBC, as well as broader sector trends like energy and industrials. Regulatory changes or currency fluctuations in these regions may also affect returns.
IDEV Top 10 Holdings
IDEV’s story is one of broad, overseas balance rather than a single star running the show. ASML has been a key engine over the year, but its recent wobble means it’s no longer pulling quite as hard. Shell is one of the brighter spots lately, giving the fund a lift from the energy patch. Big European health care names like AstraZeneca and Novartis look steady to slightly rising, while Roche and consumer staple giant Nestlé are losing a bit of steam. Financials such as HSBC and Royal Bank of Canada have been lagging, underscoring the fund’s tilt toward traditional banks across developed markets outside the U.S.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 1.90% | $505.67M | €427.52B | 82.36% | 76 Outperform | |
| AstraZeneca | 1.11% | $294.05M | $301.53B | 29.24% | 80 Outperform | |
| Novartis AG | 1.06% | $282.22M | CHF220.64B | 22.80% | 80 Outperform | |
| Roche Holding AG | 1.03% | $273.75M | $315.49B | 12.61% | 73 Outperform | |
| HSBC Holdings | 1.02% | $272.44M | £209.91B | 39.26% | 80 Outperform | |
| Shell (UK) | 1.00% | $266.43M | £201.24B | 27.67% | 73 Outperform | |
| Nestlé SA | 0.93% | $246.30M | CHF198.34B | -2.33% | 71 Outperform | |
| Royal Bank Of Canada | 0.83% | $221.68M | $225.81B | 42.35% | 75 Outperform | |
| Commonwealth Bank of Australia | 0.75% | $198.40M | AU$280.36B | 9.44% | 64 Neutral | |
| Toyota Motor | 0.74% | $195.95M | ¥41.21T | 20.20% | 80 Outperform |
IDEV Technical Analysis
Neutral
―
Price Trends
86.34
Negative
83.86
Negative
80.30
Positive
Market Momentum
-1.40
Positive
47.59
Neutral
43.99
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDEV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 83.64, equal to the 50-day MA of 86.34, and equal to the 200-day MA of 80.30, indicating a neutral trend. The MACD of -1.40 indicates Positive momentum. The RSI at 47.59 is Neutral, neither overbought nor oversold. The STOCH value of 43.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDEV.
IDEV Peer Comparison
Comparison Results
Performance Comparison
IDEV
iShares Core MSCI International Developed Markets ETF
83.57
16.71
24.99%
VEA
Vanguard FTSE Developed Markets ETF
―
―
―
SCHF
Schwab International Equity ETF
―
―
―
SPDW
SPDR Portfolio Developed World ex-US ETF
―
―
―
DFAI
Dimensional International Core Equity Market ETF
―
―
―
AVDE
Avantis International Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents